{"id":"NCT01114217","sponsor":"AMAG Pharmaceuticals, Inc.","briefTitle":"A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia","officialTitle":"A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07-27","primaryCompletion":"2012-09-24","completion":"2013-04-23","firstPosted":"2010-05-03","resultsPosted":"2018-06-11","lastUpdate":"2022-04-21"},"enrollment":634,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferumoxytol","otherNames":["Feraheme"]}],"arms":[{"label":"Ferumoxytol","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia (IDA).","primaryOutcome":{"measure":"Mean Change In Hemoglobin From TP Baseline To TP Week 5 Following The First Course Of Ferumoxytol","timeFrame":"TP Baseline (Day 1), TP Week 5","effectByArm":[{"arm":"Ferumoxytol","deltaMin":2.6,"sd":1.55}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Canada","Hungary","India","Latvia","Poland"]},"refs":{"pmids":["26572233"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":337},"commonTop":["Headache","Urinary tract infection","Nausea","Dizziness","Diarrhoea"]}}